S1 Table. Studies using stereotactic body radiation therapy for GGO-predominant lung cancer lesions

Author (year of publication)	Onishi et al. (2020) [1]	Nagata et al. (2020) [2]	Mikami et al. (2022) [3]	Our study
No. of patients (lesions)	84 (84)	48 (53)	126 (133)	89 (99)
Stage of lung cancer	cT1a-2aN0M0	cT1a-1cN0M0	cTis-2bN0M0	cTis-1cN0M0
No. of pure GGN/subsolid nodules	Median, CTR 0.26 (range, 0.0-0.5)	-	31/102	43/56
Total RT dose/fraction	Median, 48 Gy/4 fx (range, 44 Gy/4 fx-84 Gy/10 fx)	66 GyE/10fx (proton beam therapy)	50-60 Gy/5 fx (peripheral) 40 Gy/5 fx (central)	Median, 56 Gy/4 fx (range, 48 Gy/4 fx-60 Gy/4fx)
Pathologically confirmed cancer (%)	41.7	30.2	27.8	44.4
History of lung cancer (%)	9.5	22.9	35.7	57.3
Local control rate (%)	100.0	92.5 (3-yr)	100.0	100.0
Regional recurrence (%)	0.0	-	0.0	3.7 (3-yr)
Distant metastasis (%)	4.0 (2-yr)	-	0.8 (5-yr)	3.4 (crude rate)
Disease-free survival (%)	-	85.4 (3-yr)	-	92.6 (3-yr)
Overall survival (%)	94.6 (3-yr)	91.7 (3-yr)	78.0 (5-yr)	91.6 (3-yr)
RP grade ≥3 (%)	0.0 (RP ≥grade 4)	0.0	1.6	0.0

CTR, consolidation-to-tumor ratio; GGN, ground-glass nodule; GGO, ground-glass opacity; RP, radiation pneumonitis; RT, radiation therapy.

References

1. Onishi H, Shioyama Y, Matsumoto Y, Shibamoto Y, Miyakawa A, Suzuki G, et al. Stereotactic body radiotherapy in patients with lung tumors composed of mainly ground-glass opacity. J Radiat Res. 2020;61:426-30.
2. Nagata I, Ogino T, Arimura T, Yoshiura T. Clinical outcomes of proton beam therapy for ground-glass opacity-type lung cancer. Lung Cancer (Auckl). 2020;11:105-11.
3. Mikami N, Takeda A, Hashimoto A, Takeda T, Kimura Y, Oku Y, et al. CT findings and treatment outcomes of ground-glass opacity predominant lung cancer after stereotactic body radiotherapy. Clin Lung Cancer. 2022;23:428-37.